Key statistics
As of last trade Legend Biotech Corp (9LB:DUS) traded at 37.40, 7.47% above its 52-week low of 34.80, set on Nov 19, 2024.
52-week range
Open | 37.40 |
---|---|
High | 37.40 |
Low | 37.40 |
Bid | 37.40 |
Offer | 38.40 |
Previous close | 37.60 |
Average volume | 15.89 |
---|---|
Shares outstanding | 184.29m |
Free float | 181.21m |
P/E (TTM) | -- |
Market cap | 7.33bn USD |
EPS (TTM) | -1.91 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:11 GMT.
More ▼
- Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
- Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
- Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
- Legend Biotech Appoints Alan Bash as President of CARVYKTI®
- Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
- Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
- CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
- Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
- Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
More ▼